[补充材料]Anti-TL1A antibody, afimkibart, in moderately-to-severely active ulcerative colitis (TUSCANY-2): a multicentre, double-blind, treat-through, multi-dose, randomised, placebo-controlled, phase 2b trial

发表于 2026-8-22 08:51:48

DOI号:10.1016/S2468-1253(25)00129-3

文献链接:https://www.thelancet.com/journals/langas/article/PIIS2468-1253(25)00129-3/abstract

文献作者:Danese, Silvio; Allegretti, Jessica R.; Schreiber, Stefan; Peyrin-Biroulet, Laurent; Jairath, Vipul; D'Haens, Geert; Kierkuś, Jarosław; Leong, Rupert W.; Yarur, Andres J.; Vincent, Michael S.; Banerjee, Anindita; Chandra, Deepa E.; Peeva, Elena; Neelakantan, Srividya; Hung, Kenneth E.; McBride, Jacqueline M.; Bojic, Daniela; Lasch, Karen; Schiffman, Courtney; Feagan, Brian G.

备注信息:要的是这篇文章的Supplementary appendix，Supplementary appendix，Supplementary appendix（重要的事情说三遍！！！！）不要正文，正文已有，非诚勿扰，谢谢！！！

发表于 2026-8-22 08:51:49

: 当前求助已完成，请重新发起求助。
已完结状态的附件将会在24小时内删除。

发表于 2026-8-23 00:15:40

: 当前求助已完成，请重新发起求助。
已完结状态的附件将会在24小时内删除。

[Elsevier/Sciencedirect] [补充材料]Anti-TL1A antibody, afimkibart, in moderately-to-severely active ulcerative colitis (TUSCANY-2): a multicentre, double-blind, treat-through, multi-dose, randomised, placebo-controlled, phase 2b trial

已采纳

同分类求助

最新回复

站点公告

今日热心研友

（热心研友QQ群）

[Elsevier/Sciencedirect] [补充材料]Anti-TL1A antibody, afimkibart, in moderately-to-severely active ulcerative colitis (TUSCANY-2): a multicentre, double-blind, treat-through, multi-dose, randomised, placebo-controlled, phase 2b trial 一键复制